RANI (ranitherapeutics.com) Net Profit

Corporate emblem and logo of Rani Therapeutics (RANI)

The minimal environmental footprint of Rani Therapeutics (RANI) contrasts with the business's ambitions, which is confirmed by the company's profit: the indicator level is -0.03. This chart's price action smooths over concerns regarding capital shortages and the complexities of mass-producing capsules. Growth potential is driven by transferring rights for the innovative drug delivery system to corporate behemoths through licensing agreements.

RANI (ranitherapeutics.com) Company Net Income history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for ranitherapeutics.com (RANI)

- price and consensus price forecast:
Stock Quotes Rani Therapeutics Holdings, Inc.|RANI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization RANI|RANI - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Rani Therapeutics|RANI - Company Book Value|Market-to-Book Ratio ranitherapeutics.com|RANI - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Rani Therapeutics|RANI - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Rani Therapeutics Holdings, Inc.|RANI - Company Aggregate Debts|Debts to Book Value RANI|RANI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rani Therapeutics|Intermediate Coverage Ratio ranitherapeutics.com
- net income and valuation multiples indicators:
RANI - Net Profit
Fundamental valuation:RANI Rani Therapeutics Inc
Flagship merchandise of Rani Therapeutics Holdings

This indicator accumulates daily net profit, measuring cash flow stability and the business's capacity for self-financing. The current net profit value for the firm stands at -0.03, however, for Rani Therapeutics (RANI), this metric reflects a high dependence on external issuances due to significant clinical trial costs for RaniPill and the risks of technological delays.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Final Profit AQST|scPharma - Net Profit|TECX - Net Profit|Tonix Pharmaceuticals (TNXP) - Company Net Income|Company Profit SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|BioHarvest Sciences, Inc. (BHST) - Net Financial Result|Net Income EXOZ (Invizyne Technologies, Inc.)|ORMP (oramed.com) - Final Profit|Entera Bio - Net Income|Profit After Payment of Taxes HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. - Net Profit|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM: Net Profit|Company Net Income FibroGen Corporation (FGEN)|Company Net Income Telomir Pharmaceuticals|SNYR: Final Profit|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Company Net Income Pulmatrix Corp PULM|PTHL (Pheton Holdings Limited) - Profit After Tax|Aptorum - Net Profit|Company Net Income lyratherapeutics.com|IBO (Impact BioMedical Inc) - Net Income|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Net Income YCBD|PRFX (PainReform Corp) - Profit After Payment of Taxes|Net Profit CYTO|Net Financial Result lipella.com|Net Profit OPTN (OptiNose)|PIRS - Net Income|PROC - Company Net Income|Net Financial Result Petros Pharma PTPI|Qilian International (QLI) - Company Net Income|acelyrin.com - Final Profit|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit